GS 9901

Drug Profile

GS 9901

Alternative Names: GS-9901

Latest Information Update: 16 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Lymphoma

Most Recent Events

  • 01 Dec 2014 Phase-I clinical trials in Chronic lymphocytic leukaemia and Lymphoma (Second-line therapy or greater, Refractory metastatic disease) in USA (PO) (NCT02258555)
  • 08 Oct 2014 Preclinical trials in Chronic lymphocytic leukaemia in USA (PO) prior to October 2014
  • 08 Oct 2014 Preclinical trials in Follicular lymphoma in USA (PO) prior to October 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top